RxDoctor Payments Data

Paige Charleston, MD

Urogynecology and Reconstructive Pelvic Surgery · Elkhorn, NENPI 1366555369

Payments from drug & device makers

$6,229in general payments, 2019–2025

Across 167 payments — averaging $37.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axonics, Inc.$2K
  • Caldera Medical, Inc$996
  • Astellas Pharma US Inc$461
  • AbbVie$408
  • Boston Scientific$387
  • Baxter Healthcare$383
  • plus $2K from 17 others

What the payments were for

  • Travel & lodging$77312%
  • Food & beverage$5,02281%
  • Education$1993%
  • Gifts$2364%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few urogynecology and reconstructive pelvic surgery providers in Nebraskato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$292,817
Medicare patients
524
Services billed
13,288

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron171$95,456
GemtesaVibegron114$74,417
Estradiol308$22,147
PremarinEstrogens, Conjugated43$13,895
Methenamine Hippurate166$10,274
VeozahFezolinetant15$7,894
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst266$6,236
Fosfomycin Tromethamine26$4,603
Mirabegron ErMirabegron14$4,100
Trospium Chloride ErTrospium Chloride18$4,027
ImvexxyEstradiol14$3,876
Solifenacin Succinate47$2,373
Trimethoprim53$2,149
Estradiol (Twice Weekly)Estradiol14$1,884
Clobetasol Propionate38$1,817

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq, Veozah$461$103,350186 claims
Sumitomo Pharma America, Inc.Gemtesa$357$74,417114 claims
PfizerPremarin$258$13,89543 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few urogynecology and reconstructive pelvic surgery providers in Nebraskaon file to place this against a meaningful peer group, so we don't.

Other urogynecology and reconstructive pelvic surgery in Elkhorn

Where these figures come from

Is this you, or does something look wrong? →